[1]
|
Bergstrom M,Muhr C,Lundberg PO,et al. PET as a tool in the clinical evaluation of pituitary adenomas[J].J Nucl Med,1991,32:4610-4615. |
[2]
|
Brunette A,Fulham MJ,Aloj L,et al. Decreased brain glucose utilization in patients with Cushing's dis-ease[J]. J Nucl Med,1998,39(5):786-790. |
[3]
|
Meyer JH,Kennedy S,Brown GM. No effect of de-pression on [15O] H2O PET response to intravenous d-fenfluramine[J]. Am J Psychiatry,1998,155(9):1241-1246. |
[4]
|
Daemen BJ,Zwertbroek R,Elsinga PH,et al.PET studies with L-[1-11C] tyrosine,L-[methyl-11C] methion-ine and 18F-fluorodeoxyglucose in prolactinomas in rela-tion to bromocryptine treatment[J]. Eur J Nucl Med,1991,18(7):453-460. |
[5]
|
Lucignani G,Losa M,Moresco RM,et al. Differentia-tion of clinically non-functioning pituitary adenomas from meningiomas and craniopharyngiomas by positron emission tomography with [18 F] fluoro-ethyl-spiperone[J]. Eur J Nucl Med,1997,24(9):1149-1155. |
[6]
|
Stolz B,Smith JPM,Albert R,et al. Biologicalcharac-terisation of [67Ga] or [68Ga] labelled DFO-octreotide(SDZ 216-927) for PET studies of somatostatin recep-tor positive tumors[J]. Horm Metab Res,1994,26(10):453-459. |
[7]
|
Hara T,Kosaka N,Shinoura N,et al. PET imaging of brain tumor with [methyl-11C] choline[J]. J Nucl Med,1997,38(6):842-847. |
[8]
|
Wgng GJ,Volkow ND,Fowler JS,et al. Comparison of two PET radioligands for imaging extrastriatal dopamine receptors in the human brain[J]. Synapse,1993,15(3):246-249. |
[9]
|
De Herder W,Lamberts S. Imaging of pituitary tu-mours[J]. Baillieres Clin Endocrinol Metab,1995,9(2):367-389. |